Ardian looks beyond Italy with Neopharmed reinvestment

Additional equity from joint investor NB Renaissance will help the company at a 'turning point' in its history, says Ardian director Giacomo Forti.

1 December 2022•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.